116 related articles for article (PubMed ID: 19721243)
1. Glycogen phosphorylase a inhibitors with a phenethylphenylphthalimide skeleton derived from thalidomide-related alpha-glucosidase inhibitors and liver X receptor antagonists.
Motoshima K; Ishikawa M; Sugita K; Hashimoto Y
Biol Pharm Bull; 2009 Sep; 32(9):1618-20. PubMed ID: 19721243
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of restriction enzymes EcoRI, BamHI and HindIII by phenethylphenylphthalimides derived from thalidomide.
Motoshima K; Ishikawa M; Hashimoto Y; Sugita K
Chem Pharm Bull (Tokyo); 2011; 59(7):880-4. PubMed ID: 21720041
[TBL] [Abstract][Full Text] [Related]
3. Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists.
Motoshima K; Sugita K; Hashimoto Y; Ishikawa M
Bioorg Med Chem Lett; 2011 May; 21(10):3041-5. PubMed ID: 21478015
[TBL] [Abstract][Full Text] [Related]
4. Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors.
Noguchi-Yachide T; Aoyama A; Makishima M; Miyachi H; Hashimoto Y
Bioorg Med Chem Lett; 2007 Jul; 17(14):3957-61. PubMed ID: 17498949
[TBL] [Abstract][Full Text] [Related]
5. Structural development of liver X receptor (LXR) antagonists derived from thalidomide-related glucosidase inhibitors.
Noguchi-Yachide T; Miyachi H; Aoyama H; Aoyama A; Makishima M; Hashimoto Y
Chem Pharm Bull (Tokyo); 2007 Dec; 55(12):1750-4. PubMed ID: 18057753
[TBL] [Abstract][Full Text] [Related]
6. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors.
Gregus Z; Németi B
Toxicol Sci; 2007 Nov; 100(1):44-53. PubMed ID: 17693424
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.
Motoshima K; Ishikawa M; Hashimoto Y; Sugita K
Bioorg Med Chem; 2011 May; 19(10):3156-72. PubMed ID: 21514830
[TBL] [Abstract][Full Text] [Related]
8. Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists.
Motoshima K; Noguchi-Yachide T; Sugita K; Hashimoto Y; Ishikawa M
Bioorg Med Chem; 2009 Jul; 17(14):5001-14. PubMed ID: 19539483
[TBL] [Abstract][Full Text] [Related]
9. Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs.
Oikonomakos NG; Kosmopoulou MN; Chrysina ED; Leonidas DD; Kostas ID; Wendt KU; Klabunde T; Defossa E
Protein Sci; 2005 Jul; 14(7):1760-71. PubMed ID: 15987904
[TBL] [Abstract][Full Text] [Related]
10. Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development.
Dodo K; Aoyama A; Noguchi-Yachide T; Makishima M; Miyachi H; Hashimoto Y
Bioorg Med Chem; 2008 Apr; 16(8):4272-85. PubMed ID: 18343126
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide as a multi-template for development of biologically active compounds.
Hashimoto Y
Arch Pharm (Weinheim); 2008 Sep; 341(9):536-47. PubMed ID: 18389516
[TBL] [Abstract][Full Text] [Related]
12. Modeling aided design of potent glycogen phosphorylase inhibitors.
Deng Q; Lu Z; Bohn J; Ellsworth KP; Myers RW; Geissler WM; Harris G; Willoughby CA; Chapman K; McKeever B; Mosley R
J Mol Graph Model; 2005 Apr; 23(5):457-64. PubMed ID: 15781188
[TBL] [Abstract][Full Text] [Related]
13. Pentacyclic triterpenes. Part 2: Synthesis and biological evaluation of maslinic acid derivatives as glycogen phosphorylase inhibitors.
Wen X; Zhang P; Liu J; Zhang L; Wu X; Ni P; Sun H
Bioorg Med Chem Lett; 2006 Feb; 16(3):722-6. PubMed ID: 16246555
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of a C-glucosylated cyclopropylamide and evaluation as a glycogen phosphorylase inhibitor.
Bertus P; Szymoniak J; Jeanneau E; Docsa T; Gergely P; Praly JP; Vidal S
Bioorg Med Chem Lett; 2008 Sep; 18(17):4774-8. PubMed ID: 18701279
[TBL] [Abstract][Full Text] [Related]
15. Novel alpha-glucosidase inhibitors with a tetrachlorophthalimide skeleton.
Sou S; Mayumi S; Takahashi H; Yamasaki R; Kadoya S; Sodeoka M; Hashimoto Y
Bioorg Med Chem Lett; 2000 May; 10(10):1081-4. PubMed ID: 10843222
[TBL] [Abstract][Full Text] [Related]
16. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.
Klabunde T; Wendt KU; Kadereit D; Brachvogel V; Burger HJ; Herling AW; Oikonomakos NG; Kosmopoulou MN; Schmoll D; Sarubbi E; von Roedern E; Schönafinger K; Defossa E
J Med Chem; 2005 Oct; 48(20):6178-93. PubMed ID: 16190745
[TBL] [Abstract][Full Text] [Related]
17. Alpha-glucosidase inhibitors with a 4,5,6,7-tetrachlorophthalimide skeleton pendanted with a cycloalkyl or dicarba-closo-dodecaborane group.
Sou S; Takahashi H; Yamasaki R; Kagechika H; Endo Y; Hashimoto Y
Chem Pharm Bull (Tokyo); 2001 Jun; 49(6):791-3. PubMed ID: 11411542
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of phthalimide-based fluorescent liver x receptor antagonists.
Kishida K; Aoyama A; Hashimoto Y; Miyachi H
Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1525-8. PubMed ID: 21048348
[TBL] [Abstract][Full Text] [Related]
19. Development of tryptase inhibitors derived from thalidomide.
Tetsuhashi M; Ishikawa M; Hashimoto M; Hashimoto Y; Aoyama H
Bioorg Med Chem; 2010 Jul; 18(14):5323-38. PubMed ID: 20561792
[TBL] [Abstract][Full Text] [Related]
20. Phenylhomophthalimide-type NOS inhibitors derived from thalidomide.
Noguchi T; Sano H; Shimazawa R; Tanatani A; Miyachi H; Hashimoto Y
Bioorg Med Chem Lett; 2004 Aug; 14(16):4141-5. PubMed ID: 15261258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
